\
&
Contact us
\
&
Contact us
Published on | 7 months ago
Programmes European Digital Innovation HubsThe European Commission has opened a call today to aim for the Consolidation of the network of European Digital Innovation Hubs, with a reinforced AI focus.
The objective of this call is the consolidation of the network of European Digital Innovation Hubs (EDIHs) aiming to cover all regions of the European Union and Associated Countries, by strengthening its performance and capacity to meet local, regional, national and European digitalisation needs.
With increased experience and capacities, the EDIHs will continue providing the complete set of services of an EDIH, including the necessary infrastructure, focusing primarily on specific geographical areas, and covering the digital transformation needs of local SMEs, mid-caps and/or public sector organisations. Considering the transformation potential of AI technologies, these will be a reinforced focus of EDIHs’ operations under this call.
The consolidation of the EDIHs network will be pivotal in supporting the wide deployment and uptake of European AI technologies, solutions, and tools and in promoting the adoption of other crucial digital technologies, while upholding Union values and human-centric perspective.
The call is now open for submission, deadline to submit proposals is 14 May 2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
